Inclusion Criteria:

- age ≥ 65 years;

- breast or lung cancer patients to receive docetaxel therapy as per protocol;

- corticosteroid administration, other than what is prescribed in this protocol, is not
permitted during study participation, except topical administration and for adverse
events;

- performance status ECOG 0-2;

- peripheral neuropathy ≤ 1;

- adequate kidney and liver functions

- signed study-specific informed consent

Exclusion Criteria:

- Patients who have received an investigational drug within 4 weeks of registration;

- Prior or concurrent malignancies (other than surgically treated carcinoma in situ;

- Serious medical or psychiatric illness which would prevent informed consent;

- Life expectancy < 3 months;

- Active uncontrolled bacterial, viral, or fungal infection until these conditions are
corrected or controlled.